Department of Psychiatry, Central Institute of Psychiatry, Ranchi, Jharkhand, India.
Early Interv Psychiatry. 2016 Dec;10(6):522-527. doi: 10.1111/eip.12205. Epub 2014 Dec 21.
Weight gain has long been recognized as a side-effect of atypical antipsychotic drugs. Numerous new approaches have been tried for prevention of weight gain, the H2 blockers being one of them. The study was conducted with the aim to evaluate the efficacy of ranitidine in olanzapine-induced weight gain at two fixed doses of 150 and 300 mg day .
Seventy-five inpatients with an ICD-10-DCR diagnosis of schizophrenia as their first episode were randomized into three groups of 25 patients each, receiving 150 mg day ranitidine, 300 mg day ranitidine and third group receiving only olanzapine. Their weight and body mass index (BMI) were measured at baseline and at intervals of 4 and 8 weeks.
All patients were comparable with respect to their weight and BMI at baseline. When a change in the weight and BMI was assessed at 4 and 8 weeks from baseline, no significant difference was observed between the three groups.
Ranitidine at doses of 150 and 300 mg day when combined with olanzapine was ineffective in attenuating olanzapine-induced weight gain. The likely reasons could be the use of low doses for a shorter period of time, or mechanisms other than H2 receptors might play an important role in weight gain.
体重增加长期以来一直被认为是非典型抗精神病药物的副作用。人们尝试了许多新的方法来预防体重增加，其中 H2 阻滞剂就是其中之一。本研究旨在评估雷尼替丁在两种固定剂量（150 和 300mg/天）的奥氮平引起的体重增加中的疗效。
75 名 ICD-10-DCR 诊断为首发精神分裂症的住院患者被随机分为三组，每组 25 名患者，分别接受 150mg/天雷尼替丁、300mg/天雷尼替丁和第三组仅接受奥氮平治疗。在基线和 4 周和 8 周时测量他们的体重和体重指数（BMI）。
所有患者在基线时的体重和 BMI 均具有可比性。当评估从基线开始的 4 周和 8 周时体重和 BMI 的变化时，三组之间没有观察到显著差异。
当与奥氮平联合使用时，雷尼替丁的剂量为 150 和 300mg/天，对减轻奥氮平引起的体重增加无效。可能的原因是使用低剂量和较短的时间，或者 H2 受体以外的机制可能在体重增加中发挥重要作用。
